logo-loader
RNS
viewMaxCyte Inc

Updates on CARMA Platform at Upcoming Meetings

/**/ sup{font-size:80%}h1{margin-top:0cm;margin-right:0cm;margin-bottom:16.0pt;margin-left:0cm;text-align:center;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:48.0pt;margin-left:0cm;text-align:center;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:16.0pt;margin-left:0cm;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;line-height:12.0pt;border:none;padding:0cm;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h5{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;text-align:justify;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;text-align:justify;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #000000 } visited{ color: purple } .fx{size:612.0pt 792.0pt;margin:40.5pt 72.0pt 36.0pt 72.0pt;}div.fx{}p.id{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-right: .2pt; text-align: center}span.ib{line-height:115%;font-family:"Calibri","sans-serif"}span.hz{font-size:14.0pt;line-height:115%; font-family:"Calibri","sans-serif"}p.ie{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";line-height: 115%; margin-right: .2pt; text-align: center}span.hy{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}span.hx{font-size:14.0pt;line-height: 115%;font-family:"Calibri","sans-serif"}p.if{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; line-height: 115%; margin-right: .2pt; text-align: center}span.hv{font-family:"Calibri","sans-serif"; color:black} span.ht{font-size:14.0pt;line-height:115%;font-family: "Calibri","sans-serif";color:black}p.ig{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify;line-height: 115%;text-autospace:none}span.hr{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}span.hs{color:black}span.hq{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.hp{font-size:14.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.hn{font-size:11.0pt;line-height: 115%;font-family:"Calibri","sans-serif";color:black}p.ih{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-right: .2pt; text-align: justify}span.hm{font-size:11.0pt;line-height:115%;font-family: "Calibri","sans-serif"}p.ii{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-right: .2pt; text-align: justify} span.hk{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.ij{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif"; font-div: italic; font-weight: bold; margin-right: .2pt; text-align: justify}p.ik{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify;background:white}span.hh{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.hf{font-size:11.0pt;font-family:"Calibri","sans-serif"}a.he{text-decoration: underline}p.il{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;background:white}p.im{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif"; font-weight: bold; margin-right: .2pt}.hb{font-div: italic}span.ha{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black} span.gz{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.in{color:windowtext;font-size:11.0pt;font-family:"Calibri","sans-serif"}p.io{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: .2pt; text-align: justify}span.gy{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black;background:white}p.ip{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; margin-right: .2pt; text-align: justify}p.iq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify}span.gu{font-size: 11.0pt;font-family:"Calibri","sans-serif";background:white}span.gt{font-size:11.0pt;font-family:"Calibri","sans-serif";background:white}span.gs{font-size:11.0pt; font-family:"Calibri","sans-serif";background:white}p.ir{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify;line-height: 115%} span.gr{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.is{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin-right: .2pt; text-autospace: none}span.gp{font-size:11.0pt;line-height:150%;font-family: "Calibri","sans-serif";color:black}p.it{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: .2pt; text-autospace: none}table.iu{width:456.3pt;border-collapse:collapse}tr.gi{height:14.05pt}td.gk{width:242.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt}p.iv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: .2pt}p.iw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt}td.gj{width:191.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt} tr.gd{height:101.25pt}td.gf{width:242.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt}p.ix{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; margin-right: .2pt}span.gh{font-size: 11.0pt;font-family:"Calibri","sans-serif"}td.ge{width:191.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt}p.fz{font-weight: bold}span.ga{font-size:12.0pt;font-family:"Times New Roman","serif"}br.gb{page-break-before:auto}.fy{size:612.0pt 792.0pt;margin:45.0pt 72.0pt 36.0pt 72.0pt;}div.fy{} p.bh,li.bh,div.bh{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";} /**/
RNS Number : 0473O
MaxCyte, Inc.
30 September 2019
 

 

 

 

MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings

Clinical-stage CARMA platform delivers non-viral mRNA-based cell therapies

Faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

 

Gaithersburg, Maryland - 30 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces its planned participation at five upcoming meetings. These conferences and events will demonstrate how MaxCyte is driving the development of the next generation of cell-based medicines with its proprietary CARMA platform.

 

CARMA is MaxCyte's clinical-stage, non-viral, mRNA-based cell therapy platform that allows for the transfection of mRNA into cells and provides a simple, rapid-to-manufacture, dose-controllable product. CARMA requires less than one day to manufacture therapies for patients, where existing CAR-T therapies require one to two weeks or more to manufacture. MaxCyte's wholly-owned lead CARMA candidate, MCY-M11, is currently being evaluated in a Phase I clinical trial in patients with advanced ovarian cancer and peritoneal mesothelioma.

 

Details of the conferences are as follows:

 

ESMO Congress 2019

27 September - 1 October 2019, Barcelona, Spain

Christina M. Annunziata, MD, PhD, Head, Translational Genomics Section, Investigator, Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, will present a trials-in-progress poster titled: "A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy."

 

The poster session will take place at 12:20 p.m. CET on 30 September. The poster will be available after the conference on the Events section of the MaxCyte website.

 

For more information, please visit: https://www.esmo.org/Conferences/ESMO-Congress-2019

 

Cell & Gene Meeting on the Mesa

2 - 4 October 2019,  Carslbad, California 

MaxCyte's CEO Doug Doerfler will present the CARMA pipeline on Wednesday, 2 October at 2:15 p.m. PT.

For more information, please visit: https://www.meetingonthemesa.com/

 

BIO Investor Forum

22 - 23 October 2019, San Francisco, California

MaxCyte's CEO Doug Doerfler will present to attendees on the CARMA pipeline.

The timing of the presentation will be made available closer to the start of the conference. For more information, please visit: https://www.bio.org/events/bio-investor-forum

 

Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting/SITC 2019

6 - 10 November 2019, National Harbor, MD

MaxCyte Director Technical Operations Robert Keefe, PhD, will present a poster titled: "Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology" on Saturday, 9 November from 7 a.m. to 8:30 p.m. ET.

For more information, please visit: https://www.sitcancer.org/2019/home

 

BIO-Europe 2019

11 - 13 November 2019, Hamburg Germany

MaxCyte CEO Doug Doerfler will present to attendees on the CARMA pipeline.

The timing of the presentation will be made available closer to the start of the conference. For more information, please visit: https://ebdgroup.knect365.com/bioeurope/

 

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

[email protected]


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDLLMPTMBATBIL

Quick facts: MaxCyte Inc

Price: 107.5

Market: AIM
Market Cap: £61.69 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18